Core Insights - The issuance of investable Hong Kong stock funds has significantly rebounded in Q3 2025, reaching the highest level since Q1 2021 [2] - The active public fund's allocation to Hong Kong stocks has slightly decreased, with the market value proportion of Hong Kong stocks in active equity funds dropping from 20.0% in Q2 2025 to 19.2% in Q3 2025 [2] Fund Issuance - In Q3 2025, the issuance of public funds that can invest in Hong Kong stocks through the Stock Connect has increased on a month-on-month basis, marking a new high since Q1 2021 [2] Fund Positioning - The active public funds have slightly reduced their positions in Hong Kong stocks, with the market value proportion of Hong Kong stocks in their portfolios decreasing from 20.0% in Q2 2025 to 19.2% in Q3 2025 [2] - The allocation to Hong Kong small-cap stocks and technology stocks has increased, with the market value proportion rising by 1.1 and 3.0 percentage points respectively [2] Sector Analysis - In Q3 2025, public funds primarily increased their holdings in the retail, pharmaceutical, and non-ferrous metal sectors, focusing on concepts such as internet retail, semiconductors, and innovative pharmaceuticals [2] - Conversely, there was a reduction in holdings in the communication, computer, social services, light industry, and automotive sectors, which include concepts like communication equipment, new consumption, and new energy vehicles [2]

Group 1 - The core viewpoint of the report highlights the explosive growth of the global Brain-Computer Interface (BCI) industry in the fields of neuroengineering and medical rehabilitation during 2023-2024, driven by collaborative innovations in both invasive and non-invasive technologies [3][8] - Significant advancements in BCI technology include improvements in hardware and software optimization, with the latest AFE achieving a CMRR of 140 dB and system-level CMRR exceeding 80 dB [8] - Clinical applications of BCI are expanding to address conditions such as stroke, spinal cord injury, ALS, and depression, with invasive systems providing precise interventions for severe cases and non-invasive systems enhancing accessibility [9] Group 2 - The report reviews the performance of the pharmaceutical sector from October 20 to October 24, noting that the medical services and pharmaceutical commercial sectors had the highest gains, with increases of 3.94% and 2.27% respectively [10] - The report indicates that the biopharmaceutical and traditional Chinese medicine sectors experienced declines of -0.69% and -0.85% respectively during the same period [10][12] - The report emphasizes the strong performance of the innovative drug sector, with 22 innovative drug-themed funds achieving a net asset value growth rate exceeding 50% year-to-date, reflecting the increasing competitiveness of Chinese innovative drugs globally [28][29]

Report Industry Investment Rating No relevant content provided. Core Views of the Report - The Fourth Plenary Session of the 20th CPC Central Committee provides a favorable risk - preference environment for the bull market of Chinese - funded stocks. The overall tone of the plenary session rules out the probability of macro - tail risks and emphasizes the continuous and timely strengthening of macro - policies to achieve annual economic and social development goals [2][3]. - During the 15th Five - Year Plan period, the development of the science and technology industry will be placed in a relatively prominent position. The three important main lines of the 15th Five - Year Plan are national security, scientific and technological self - reliance and industrial innovation, and benefiting people's livelihood and promoting consumption [4][5][6]. - "Science and technology" is the main investment line during the 15th Five - Year Plan period. Strategic emerging industries such as artificial intelligence and biological manufacturing are key investment opportunities, and some new consumption tracks are also worthy of attention [8][9]. - Currently, the valuation of Chinese - funded stocks is in a reasonable range. Structurally, the valuation cost - performance of the technology sectors in A - shares and Hong Kong stocks is higher than that of the broader market indices. The high valuation of Chinese technology assets matches the high growth rate, and the valuation gap between Chinese and US technology assets is expected to narrow [10][14][18]. - The trend of emerging industries represented by the AI industry chain is becoming clearer. A - shares focus on upstream computing power hardware, while Hong Kong stocks focus on mid - stream Internet giants and downstream software applications. The performance realization path of the AI industry chain of Chinese - funded stocks generally follows the order of computing power chips → infrastructure giants' IaaS → application - end software/media [22][23][26]. - The emerging industry trend represented by innovative drugs is becoming clearer. The innovative drug sector has begun to release performance, and the shift from "local commercialization" to "going global" is the key driving force for the leap - forward development of the innovative drug sector [33][34][35]. - In the short term, the earnings season may increase the volatility of the Chinese - funded stock market. TACO trading can be "batch - wise" bought at low prices, with a focus on technology assets. In the medium term, Chinese - funded stocks maintain a barbell strategy, with A - shares for offense and Hong Kong stocks for defense [37][38]. Summary by Relevant Catalogs 1. Policy Environment and Investment Direction during the 15th Five - Year Plan - **Policy Timeline**: In October 2025, the Fourth Plenary Session of the 20th CPC Central Committee released a communiqué to set the direction for the 15th Five - Year Plan. In 2026, the central government will release a draft proposal for the plan, and the Two Sessions will review and release the "Outline" with specific quantitative targets. In the second half of 2026, ministries may start to promote the implementation of special and industry plans [2]. - **Policy Focus**: The Fourth Plenary Session emphasized the continuous and timely strengthening of macro - policies, aiming to achieve annual economic and social development goals, stabilize employment, enterprises, markets, and expectations, and resolve local government debt risks [3]. - **Investment Main Lines**: The three main lines are national security, scientific and technological self - reliance and industrial innovation, and benefiting people's livelihood and promoting consumption. The frequency of mentions of "science and technology" and "industry" in the Fourth Plenary Session communiqué has significantly increased compared to the Third Plenary Session, indicating that the 15th Five - Year Plan may prioritize the development of these two dimensions [5][6]. 2. Valuation Analysis of Chinese - Funded Stocks - **Forward PE**: The forward PE of the broader market indices of A - shares and Hong Kong stocks (Hang Seng Index/Shanghai Composite Index) has reached around the average + 1 STD in the past 10 years, while the forward PE of the technology sector indices (Hang Seng Information Technology Index/GEM Index) has only reached around the 10 - year average, indicating that the technology sectors in A - shares and Hong Kong stocks have higher valuation cost - performance [14]. - **PEG**: Based on the 3 - year EPS compound growth rate, the PEG of the Hang Seng Technology Index, Hang Seng Information Technology Index, and GEM Index is lower than that of the Nasdaq and S&P 500, showing that the high valuation of Chinese technology assets matches the high growth rate [18]. - **PB - ROE**: With the continuous improvement of the profitability of Chinese technology companies, the valuation gap between Chinese and US technology assets is expected to narrow due to factors such as the mapping of overseas AI assets, the huge domestic demand potential of the Chinese market, and long - term strategic policy support [19][21]. 3. AI Industry Chain Analysis - **Industrial Focus**: A - shares focus on upstream computing power hardware, including chips, PCBs, AI server assembly, and network solution providers. Hong Kong stocks focus on mid - stream Internet giants and downstream software applications, covering model development, deep - learning frameworks, and various AI - related application fields [22][23][24]. - **Performance Realization Path**: The performance realization path of the AI industry chain of Chinese - funded stocks generally follows the order of computing power chips → infrastructure giants' IaaS → application - end software/media. Upstream, the performance of A - share light modules, PCBs, and server OEMs driven by external demand is realized first, followed by GPU/chip manufacturing and AI infrastructure platforms driven by domestic demand. In the application layer, the payment willingness for AI products is relatively lagging, and the monetization business models in most fields are still being verified [26][27]. - **Market Performance**: Benefiting from the explosive growth of global AI computing power demand, some advantageous segments of the A - share AI industry chain (PCB/light module/server assembly segments) have achieved significant stock price increases driven by EPS. The capital expenditure of cloud service providers in China and the US is still rising, and the prosperity of the AI industry chain is expected to continue to climb [28][30][32]. 4. Innovative Drug Industry Analysis - **Performance Release**: The innovative drug sector has begun to release performance, with many innovative drug companies showing positive revenue year - on - year growth rates. In contrast, the traditional drug sector and some CXO companies have relatively poor performance [34]. - **Development Trend**: The shift from "local commercialization" to "going global" is the key driving force for the leap - forward development of the innovative drug sector. The innovative drug index still has about a 40% recovery space compared to the high point in 2021, indicating considerable growth potential [34][35]. 5. Investment Strategy for Chinese - Funded Stocks - **Short - Term Strategy**: In the short term, the earnings season may increase the volatility of the Chinese - funded stock market. TACO trading can be "batch - wise" bought at low prices, with a focus on technology assets such as the AI industry chain, innovative drugs, and self - controllable sectors. The Hang Seng Technology Index with higher odds and cost - performance is the top - recommended direction for Hong Kong stocks [37][38]. - **Medium - Term Strategy**: In the medium term, Chinese - funded stocks maintain a barbell strategy. A - shares are more suitable for offense, focusing on technology themes and anti - involution industries. Hong Kong stocks are more suitable for defense, including Internet, new consumption, innovative drugs, and banking and large - scale financial sectors [38].

Core Viewpoint - The report highlights the growth in equity fund sizes and emphasizes that technology sectors remain a core investment focus for prominent fund managers as they navigate market fluctuations and structural changes in the economy [1]. Group 1: Fund Manager Insights - Zhang Kun maintains a total fund size of 56.544 billion yuan, with significant gains across multiple funds, including over 15% returns for several products [2]. - The top ten holdings in Zhang Kun's portfolio include Tencent Holdings (9.94%), Alibaba (9.93%), and Kweichow Moutai (9.08%), reflecting a focus on companies with strong business models and competitive advantages [3][5]. - Guan Lan, managing 43.544 billion yuan, sees substantial performance in healthcare-related funds, with returns exceeding benchmarks, and emphasizes the ongoing potential in innovative pharmaceuticals and medical devices [9][11]. Group 2: Economic and Market Analysis - The report discusses the structural differentiation in China's economy, with a focus on the recovery of domestic demand amidst external fluctuations, particularly in the innovative drug sector [9][11]. - Liu Yanchun, managing 35.860 billion yuan, suggests that China may emerge from a prolonged period of low prices, driven by technological advancements and supportive policies [12][13]. - The report indicates that the current low valuation levels in the market provide a safety margin for long-term investments, particularly in the consumer sector, which is expected to grow faster than global GDP [6][8]. Group 3: Investment Strategies - Fund managers are focusing on high-growth sectors such as technology, healthcare, and consumer goods, with an emphasis on companies benefiting from industry growth and innovation [15][19]. - The report notes that the investment approach will continue to prioritize companies with strong fundamentals and long-term growth potential, despite short-term market volatility [19]. - The upcoming macroeconomic events, including the Central Economic Work Conference, are expected to provide important insights for long-term investment strategies [16].

Group 1 - The first Hong Kong ETF focused on "hard" technology, specifically semiconductor chips, electronics, and computer software, is set to launch on October 27 [1][2] - The Hong Kong Automotive 50 ETF, which focuses on leading car manufacturers, is expected to be launched soon [1][2] - The Hong Kong Internet ETF is designed to invest in major internet giants in the region [1][2] Group 2 - The Hong Kong Innovation Drug ETF is 100% focused on innovative pharmaceuticals [1][3] - The Hong Kong Large Cap 30 ETF combines technology and dividend strategies [1][3] - The Hong Kong Dividend ETF offers high dividend yields with low volatility [1][3] Group 3 - The Hong Kong Small Cap LOF targets small and mid-cap assets [1][3] - The Value Fund LOF focuses on A+H shares with dividend characteristics [1][3] - The new consumption wave driven by Generation Z is highlighted through the Huabao CSI Shanghai-Hong Kong-Shenzhen New Consumption Index [1][3]

Core Viewpoint - The article discusses the recent trend of profit-taking in the innovative drug sector and the shift towards increasing allocations in the power equipment sector, highlighting the changing dynamics in investment strategies within the healthcare and technology industries [1][3]. Summary by Sections Innovative Drug Sector - The innovative drug sector has seen a significant rise of over 60% in the first half of the year, but has been in a high-level consolidation phase recently [3]. - Despite the average loss of nearly 8% among 28 ETFs tracking the innovative drug index since its peak on August 19, 2025, many funds have seen their shares increase, with some growing by over 100%-300% as investors rush to buy the dip [5]. - Fund manager Jin Xiaofei has significantly reduced his holdings in innovative drugs, indicating a shift in strategy as the sector's overall gains have been substantial, leading to a crowded trade [10][14]. Fund Performance and Adjustments - Jin Xiaofei's fund, Penghua Medical Technology Stock A, has shown a year-to-date return of 22.03% in Q3, outperforming its benchmark and the CSI 300 index [8]. - The fund's exposure to the pharmaceutical and biotechnology sector has decreased to 49.5%, a reduction of over 25 percentage points, reflecting a strategic pivot [10][14]. - The top ten holdings of the fund now include a mix of innovative drugs and medical device companies, indicating a broader industry coverage [12]. Future Outlook - Jin Xiaofei remains optimistic about the long-term prospects of innovative drugs but acknowledges that the ease of making profits in this sector may be over, shifting focus to identifying stocks with real competitive advantages [15]. - Other fund managers, such as Zhao Bei from ICBC Credit Suisse, have also expressed caution regarding overvalued innovative drug companies, favoring investments in the CXO sector and companies with significant overseas revenue [16][17]. - Investors holding innovative drug stocks should temper their short-term expectations and prepare for a longer investment horizon [18]. Shift to Power Equipment Sector - The fund has made substantial reallocations, reducing its pharmaceutical holdings to 23.3% and increasing its stake in the power equipment sector to 17.2% [19][23]. - New investments include companies like Pylon Technologies and Ganfeng Lithium, indicating a strategic shift towards sectors with perceived growth potential [24].

Core Viewpoint - Despite significant business development (BD) agreements exceeding $10 billion, the stock prices of innovative pharmaceutical companies remain sluggish, indicating a disconnect between market expectations and actual performance [1][2]. Group 1: Market Performance - The Hong Kong Stock Connect innovative drug index has declined from over 1240 points on October 9 to 1110 points, reflecting a drop of approximately 10.5% [1][2]. - Notable companies like 信达生物 (Innovent Biologics) have seen their stock prices fall despite announcing major collaborations, with 信达生物's stock dropping 1.96% to 85.2 HKD per share on October 22 [2]. - Over the past month, the innovative drug sector has experienced a 16% decline from a peak of 1326 points on September 8, with several companies like 诺诚健华 (Nocera) and 康诺亚-B (CanSino) seeing stock drops exceeding 19% [2][4]. Group 2: Financial Performance - Many innovative drug companies have reported revenue growth, yet profitability remains a concern, with only four out of the listed companies achieving positive net profits [6][7]. - 康诺亚-B reported a staggering 812.1% year-on-year revenue increase, while other companies like 诺诚健华 and 信达生物 also showed significant revenue growth of over 40% [6][7]. Group 3: Industry Dynamics - The innovative drug sector is characterized by high competition and a high rate of project failure, with a significant percentage of BD agreements facing termination [8]. - The long-term outlook for the Chinese innovative drug industry remains positive, driven by an increase in BD transactions, although the market is becoming increasingly competitive [8][9]. - Analysts suggest that the recent stock price adjustments may be a result of previously overly optimistic expectations regarding BD agreements, and the market may be entering a phase of stabilization [10].

Group 1 - The underlying logic of family asset allocation is being restructured, moving away from reliance on single assets to a diversified global asset allocation approach [1] - The podcast discusses how families can leverage global technological trends for asset management [1] Group 2 - The Hong Kong stock market, particularly in the technology sector, is gaining attention due to improved fundamentals and positive expectations, making it a valuable long-term investment [4] - Many companies listed in Hong Kong are familiar to mainland investors, providing a sense of comfort and understanding [4] Group 3 - High volatility in technology assets requires investors to be aware of potential pitfalls and to adopt strategies that align with their risk tolerance [5] - A systematic investment approach, such as dollar-cost averaging, may yield better results in volatile markets [5] Group 4 - The innovative pharmaceutical sector is experiencing a reversal after two years of stagnation, driven by changes in payment policies and ongoing support from the government [6][7] - Chinese innovative drug companies are positioned as a "pharmaceutical supermarket" globally, benefiting from lower costs and a wide range of products, particularly in oncology [7] Group 5 - The lithium battery sector is witnessing a second growth curve due to explosive growth in energy storage demand, driven by technological advancements and new applications [9][10] - Recent policy changes, such as capacity pricing, are further boosting the demand for energy storage batteries [10] Group 6 - India is emerging as a new focus for global investment due to its stable currency, young population, and low labor costs, indicating a high potential for economic growth [11]

Group 1 - The Shanghai Composite Index has surpassed the 4000-point mark for the first time in ten years, with a year-to-date increase of 19.8%, indicating a significant bullish market sentiment [1] - The domestic ETF market has reached a scale of 5.72 trillion yuan, reflecting its growing influence on the market [2] - Investors are increasingly seeking balance between stable and growth-oriented assets, with funds flowing into both the A500 index and the Hang Seng Innovation Drug sector [2][20] Group 2 - The A500 ETF has seen a net inflow of over 5.6 billion yuan since the second half of the year, making it the largest ETF in the Shenzhen market [3] - The A500 index covers 500 stocks with large market capitalization and good liquidity across all major industries, achieving nearly full coverage of the A-share market [5] - The A500 index has a year-to-date return of 22.8%, outperforming the Shanghai Composite Index's 19.2% increase [6] Group 3 - The current valuation of the A500 index is 17 times earnings, which is lower than the S&P 500's 30 times earnings, while its dividend yield of 2.33% is higher than that of the S&P 500 [10][11] - The Hang Seng Innovation Drug sector has attracted over 1.2 billion yuan in net inflows since October, despite recent adjustments in the market [13] - The fourth quarter is expected to bring multiple catalysts for the innovation drug sector, including significant academic conferences and a busy period for business development transactions [16] Group 4 - The A500 index represents a balanced investment approach, while the Hang Seng Innovation Drug sector offers high-growth potential, indicating a dual-path investment strategy [20][21] - Both the A500 and the innovation drug sector reflect a positive outlook on Chinese assets, showcasing the diversity of investment opportunities [22][24]

Group 1: Stock Movements - C He Yuan's stock surged by 28.56% in the afternoon, triggering a trading halt, and after resuming, it rose over 29% during intraday trading [2] - The photovoltaic sector experienced a rally, with companies like Longi Green Energy (601012), Canadian Solar (688472), and Hongyuan Green Energy hitting the daily limit [4] Group 2: Energy Storage Sector - The energy storage sector saw significant gains, with Sunshine Power (300274) increasing by over 17%, reaching a market capitalization of over 400 billion yuan; Tongrun Equipment and Keli Ke also hit the daily limit, while Haibo Sichuang and Airo Energy rose by over 10% [7] - Sunshine Power reported a net profit of 11.9 billion yuan for the first three quarters, a 56% year-on-year increase, surpassing the total profit for the entire year of 2024 [7] Group 3: Silicon Futures - The main contract for polysilicon futures rose by over 2%, reaching 55,805 yuan per ton [8] Group 4: Innovative Drug Sector - The innovative drug sector showed upward movement, with Nossger hitting the daily limit and companies like Prusis rising over 15%; other notable gainers included Kangzhi Pharmaceutical, Tigermed, and Kanglong Chemical [9][10] - Nossger announced a net profit of 34.45 million yuan for the third quarter, a year-on-year increase of 32.98% [10]